The platform technology of Coretag provides options for the development of various diagnostic applications. Coretag Diagnostics aims to establish partnerships with oncologists, radiologists, heart specialists and neurologists and their respective clinics, for setting up clinical trials and developments for EMA and FDA approval for the further development of its pipeline of diagnostic radioligands.
Besides this Coretag aims to partner with big data-, software- and medical imaging companies for the development of screening protocols and medical devices which cooperate with its diagnostic radioligands.
Our pipeline currently consists of NC-Scan & NC-Cam:
NC-Scan (necrotic cell scan) is a diagnostic radioligand which detects and quantifies necrosis in the human with a full-body PET-scan, SPECT-scan or MRI-Scan within 24-hours after intravenous administration of NC-Scan in the patient.
With NC-Scan it not only becomes clear if the human body contains necrosis, it also provides precise information about the location and quantity of the necrosis. Based on NC-Scan various clinical applications can be developed:
- Detecting necrotic tissue in the human body, which indicates medical issues
- Detecting tumors and metastases
- Determine chemotherapy efficacy within 24-36 hours after the first administation
- Determine immunotherapy efficacy within 24-36 hours after the first administation
- Monitoring the effects of radiotherapy to improve the results during treatment plan
- Measuring and visualizing the recovery process of a heart muscle from a myocardial infarction
- Measuring and visualizing the recovery process of a stroke in the brain
- Measuring and visualizing the recovery process of a parapelia
- Screening for aggressively growing tumors
Coretag delivers NC-Tracer to the clinic where it is prepared for administration by labelling with a radiolabel. 24-hours after intravenous administration of NC-Scan in the patient, the PET, PET-CT, MRI or SPECT bodyscan provides all information about the appearance, location and quantity of necrosis in the patient.
Imaging with PET, PET-CT, MRI and SPECT:
The necrosis probe of Coretag is fluorescent which means it is detectable with a near-infrared camera. With this technology Coretag aims to develop applications for detecting necrosis without labelling its necrosis tracer with a radio-label.
Because near-infrared light penetrates 3-4 cm in the human body, applications for NC-Cam are focusing on necrosis which appears in the skin, or close under the skin, for instance in the mucous membrane.
With NC-Cam during a surgery necrosis can be visualized on a camera, which help the surgeon to become 100% certain about the removal of necrotic tissue and saving the healthy tissue.
Detecting necrosis with a near-infrared camera, without any labeling required: